Ultragenyx Pharmaceutical Stock Performance
as on September 19, 2026 at 2:15 pm IST
Day's Low
Day's High
$14.07$15.07
3.03%
Downside
3.86%
Upside
52 Week's Low
52 Week's High
$12.73$39.8912.27%
Downside
174.91%
Upside
Ultragenyx Pharmaceutical share price movements today
- Previous Close
- $14.50
- Open
- $14.75
- Volume
- 8.9M
- Market Cap
- $1.3B
- Day's Low - High
- $14.07 - $15.07
- 52 Week Low - High
- $12.73 - $39.89
Ultragenyx Pharmaceutical Historical Returns
- 1 Month Return
- -44.74 %
- 3 Month Return
- -47.16 %
- 1 Year Return
- -48.45 %
- 3 Year Return
- -60.15 %
- 5 Year Return
- -85.24 %
Ultragenyx Pharmaceutical Stock Fundamentals & Key Indicators
Check Ultragenyx Pharmaceutical market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.
Market Cap
$1.3B
EPS (TTM)
-3.8739
Dividend Yield
0.00%
Quarterly Earnings Growth YOY
0.00%
PE Ratio (TTM)
0PEG Ratio
-0.24
EBITDA
-
Revenue (TTM)
-
Profit Margin
-81.73%
Return On Equity TTM
-608.47%
Ultragenyx Pharmaceutical vs Peer Comparison
Compare market cap, revenue, PE, and other key metrics of Ultragenyx Pharmaceutical with its industry peers.
Company | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin % | Dividend Yield % |
|---|---|---|---|---|---|---|
| BUY | $1.3B | -85.24% | NA | -81.73% | 0.00% | |
| BUY | $63.1B | -63.24% | -19.81 | -12.57% | 0.00% | |
| BUY | $130.1B | 174.21% | 29.81 | 86.04% | 0.00% | |
| BUY | $79.7B | 21.1% | 18.48 | 84.86% | 0.48% |
Stock Returns calculator for Ultragenyx Pharmaceutical Stock including INR - Dollar returns
The Ultragenyx Pharmaceutical stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.
*Dollar Impact: The bonus return you make when the US Dollar rises against the Rupee; calculated on the full amount you walk away with, not just what you invested in.
Investment Value
₹1,00,000
Ultragenyx Pharmaceutical investment value today
Current value as on today
₹56,008
Returns
Returns from Ultragenyx Pharmaceutical Stock
Dollar Impact
₹4,426 (+4.43%)
Analyst Recommendation on Ultragenyx Pharmaceutical Stock
Based on 20 analysts
50.00%
Buy
50.00%
Hold
0.00%
Sell
Based on 20 analysts, 50% of analysts recommend a 'BUY' rating for Ultragenyx Pharmaceutical. Average target price of $27
Ultragenyx Pharmaceutical Share Price Target
Get share price movements and forecasts by analysts on Ultragenyx Pharmaceutical.
What analysts predicted
46.26%UPSIDE
Target Price
$27
Current Price
$14.51
Analyzed by
20 Analysts
Target
$27.00
Ultragenyx Pharmaceutical target price $27, a slight upside of 46.26% compared to current price of $14.51. According to 20 analysts rating.
Indian Investors' Interest in Ultragenyx Pharmaceutical Stock
Investment in Ultragenyx Pharmaceutical Shares on INDmoney has grown by 1183.33% in the last 30 days, indicating increased investment activity.
Time period: to
Change:1183.33% versus previous 30 day period
Search interest for Ultragenyx Pharmaceutical Stock has increased by 520% in the last 30 days, reflecting an upward trend in search activity.
Time period: to
Change:520% versus previous 30 day period
Ultragenyx Pharmaceutical Quarterly Profit & Loss
All numbers in Millions USD
Ultragenyx Pharmaceutical Annual Profit & Loss
All numbers in Millions USD
Ultragenyx Pharmaceutical News & Key Events
Today's Timeline - 18 September
Fri, 04:40 PM
-Cantor Fitzgerald raises Ultragenyx price target to $39, citing FAYUVI approval as a crucial win for the company.
Fri, 05:05 PM
-Abeona Therapeutics congratulates Ultragenyx on FDA approval of FAYUVI for Sanfilippo syndrome Type A, marking a significant milestone.
Fri, 06:35 PM
-Morgan Stanley raises Ultragenyx price target to $20, maintaining Equal Weight rating amid FAYUVI's approval.
Today's Timeline - 18 September
Fri, 07:38 PM
-Ultragenyx sets Fayuvi's price at $3.95 million, launching one of the world's most expensive drugs for a rare disease.
Insights on Ultragenyx Pharmaceutical
Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.
POSITIVE IMPACTPrice Rise
In the last 7 days, RARE stock has moved up by 6.6%
- POSITIVE IMPACT
Profit Spike
Netprofit is up for the last 2 quarters, -185.00M → -92.00M (in $), with an average increase of 101.1% per quarter
- POSITIVE IMPACT
Revenue Rich
Revenue is up for the last 2 quarters, 136.0M → 214.00M (in $), with an average increase of 36.5% per quarter
NO EFFECTAgainst Peers
In the last 3 years, Moderna, Inc. Common Stock has given 53.7% return, outperforming this stock by 114.1%
- NO EFFECT
Against Peers
In the last 1 year, Moderna, Inc. Common Stock has given 510.3% return, outperforming this stock by 558.7%
About Ultragenyx Pharmaceutical
| Organisation | Ultragenyx Pharmaceutical |
| Headquarters | 60 Leveroni Court, Novato, CA, 94949, US |
| Industry | Biotechnology |
| CEO | Emil D. Kakkis |
| E-voting on shares | Click here to vote |
Key Management of Ultragenyx Pharmaceutical
Name | Title |
|---|---|
Mr. John Richard Pinion II | Chief Quality Operations Officer & Executive VP of Translational Sciences |
Dr. Emil D. Kakkis M.D., Ph.D. | Founder, President, CEO & Director |
Mr. Erik Harris M.B.A. | Executive VP & Chief Commercial Officer |
Dr. Eric Crombez M.D. | Chief Medical Officer & Executive VP |
Mr. Theodore A. Huizenga | Senior VP, Corporate Controller & Principal Accounting Officer |
Mr. Vimal Srivastava | Senior Vice President of Business Development & Alliance Management |
Mr. Dennis Karl Huang | Chief Technical Operations Officer and Executive VP of Gene Therapy Operations |
Mr. Howard Horn | Executive VP of Corporate Strategy & CFO |
Ms. Karah Herdman Parschauer J.D. | Chief Legal Officer & Executive VP of Corporate Affairs |
Mr. Ernie W. Meyer | Chief Human Resources Officer & Executive VP |
FAQs
What is Ultragenyx Pharmaceutical share price today?
Ultragenyx Pharmaceutical share price today is $14.51 as on at the close of the market. Ultragenyx Pharmaceutical share today touched a day high of $15.07 and a low of $14.07.
What is the 52 week high and 52 week low for Ultragenyx Pharmaceutical share?
Ultragenyx Pharmaceutical share touched a 52 week high of $39.89 on and a 52 week low of $12.73 on . Ultragenyx Pharmaceutical stock price today i.e. is closed at $14.51,which is 63.62% down from its 52 week high and 13.98% up from its 52 week low.
What is Ultragenyx Pharmaceutical's market capitalisation today?
Ultragenyx Pharmaceutical market capitalisation is $0.00T as on .
How to invest in Ultragenyx Pharmaceutical Stock (RARE) from India?
- Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
- Step 2: Search for Ultragenyx Pharmaceutical on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Ultragenyx Pharmaceutical Shares that will get you 0.1034 shares as per Ultragenyx Pharmaceutical share price of $14.51 per share as on September 19, 2026 at 8:45 am IST.
What is the minimum amount required to buy Ultragenyx Pharmaceutical Stock (RARE) from India?
Indian investors can start investing in Ultragenyx Pharmaceutical (RARE) shares with as little as ₹95.88 or $1 (as of ) using the INDmoney app.
For example: If you want to invest $10 or ₹958.80 in Ultragenyx Pharmaceutical stock (as per the Rupee-Dollar exchange rate as on ).
Based on Ultragenyx Pharmaceutical share’s latest price of $14.51 as on September 19, 2026 at 8:45 am IST, you will get 0.6892 shares of Ultragenyx Pharmaceutical. Learn more about
fractional shares .
What are the returns that Ultragenyx Pharmaceutical has given to Indian investors in the last 5 years?
Ultragenyx Pharmaceutical stock has given -85.24% share price returns and 30.25% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?